Pluri Inc. Cash Flow Conversion Efficiency
Pluri Inc. cash flow conversion efficiency. Based on the latest financial reports, Pluri Inc. (PLUR) has a cash flow conversion efficiency ratio of 0.347x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.51 Million) by net assets ($-13.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pluri Inc. (2002–2025)
Cash flow conversion efficiency of Pluri Inc. from 2002 to 2025. This chart illustrates how Pluri Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Pluri Inc. (PLUR) stock price for real-time trading data and today's change.
Pluri Inc. Cash Flow Conversion Ratio Explained
Pluri Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pluri Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pluri Inc. ranked by their cash flow conversion efficiency. Also see Pluri Inc. market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Perfect Moment Ltd.
NASDAQ:PMNT
|
-7.386x |
|
Getin Holding SA
WAR:GTN
|
0.068x |
|
Adler Group SA
F:ADJ
|
-0.053x |
|
Stradim Espace Finances SA
PA:ALSAS
|
0.150x |
|
TRC Construction Public Company Limited
BK:TRC
|
0.069x |
|
Ping An Biomedical Co., Ltd.
NASDAQ:PASW
|
N/A |
|
HWH International Inc
NASDAQ:HWH
|
0.171x |
|
Donegal Investment Group PLC
IR:DQ7A
|
-0.234x |
Annual Cash Flow Conversion Efficiency for Pluri Inc. (2002–2025)
The table below shows the annual cash flow conversion efficiency of Pluri Inc. from 2002 to 2025. Review cash generation quality of Pluri Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-865.00K | $-18.21 Million | 21.053x | +732.61% |
| 2024-06-30 | $5.42 Million | $-18.02 Million | -3.328x | -122.77% |
| 2023-06-30 | $15.30 Million | $-22.86 Million | -1.494x | -31.73% |
| 2022-06-30 | $32.19 Million | $-36.50 Million | -1.134x | -109.68% |
| 2021-06-30 | $57.15 Million | $-30.91 Million | -0.541x | -15.07% |
| 2020-06-30 | $56.10 Million | $-26.37 Million | -0.470x | +65.18% |
| 2019-06-30 | $21.82 Million | $-29.45 Million | -1.350x | -79.97% |
| 2018-06-30 | $28.51 Million | $-21.38 Million | -0.750x | -4.98% |
| 2017-06-30 | $30.25 Million | $-21.61 Million | -0.714x | -47.17% |
| 2016-06-30 | $38.16 Million | $-18.52 Million | -0.485x | -36.98% |
| 2015-06-30 | $58.14 Million | $-20.61 Million | -0.354x | -15.14% |
| 2014-06-30 | $62.12 Million | $-19.12 Million | -0.308x | -4.74% |
| 2013-06-30 | $57.47 Million | $-16.89 Million | -0.294x | -238.65% |
| 2012-06-30 | $37.74 Million | $-3.27 Million | -0.087x | +34.53% |
| 2011-06-30 | $43.42 Million | $-5.75 Million | -0.133x | +90.24% |
| 2010-06-30 | $3.98 Million | $-5.41 Million | -1.358x | -8.18% |
| 2009-06-30 | $3.39 Million | $-4.26 Million | -1.256x | +35.54% |
| 2008-06-30 | $2.33 Million | $-4.54 Million | -1.948x | -274.03% |
| 2007-06-30 | $5.90 Million | $-3.07 Million | -0.521x | -116.39% |
| 2006-06-30 | $-644.23K | $-2.05 Million | 3.178x | +419.78% |
| 2005-06-30 | $1.80 Million | $-1.79 Million | -0.994x | +76.53% |
| 2004-06-30 | $357.01K | $-1.51 Million | -4.234x | -434.85% |
| 2003-06-30 | $490.42K | $-388.27K | -0.792x | -193.05% |
| 2002-06-30 | $-75.40K | $-64.16K | 0.851x | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, … Read more